P
Paloma Jara
Researcher at Hospital Universitario La Paz
Publications - 100
Citations - 3193
Paloma Jara is an academic researcher from Hospital Universitario La Paz. The author has contributed to research in topics: Liver transplantation & Transplantation. The author has an hindex of 29, co-authored 99 publications receiving 3046 citations. Previous affiliations of Paloma Jara include Autonomous University of Madrid.
Papers
More filters
Journal ArticleDOI
NOTCH2 mutations in Alagille syndrome
Binita M. Kamath,Robert C. Bauer,Kathleen M. Loomes,Grace Chao,Jennifer Gerfen,Anne L. Hutchinson,Winita Hardikar,Gideon M. Hirschfield,Paloma Jara,Ian D. Krantz,Pablo Lapunzina,Laura D Leonard,Simon C. Ling,Vicky L. Ng,Phuc Le Hoang,David A. Piccoli,Nancy B. Spinner +16 more
TL;DR: The importance of NOTCH2 as a second disease gene in ALGS is confirmed and the repertoire of the Notch2 related disease phenotype is expanded.
Journal ArticleDOI
Chronic hepatitis C virus infection in childhood: clinical patterns and evolution in 224 white children.
Paloma Jara,Massimo Resti,Loreto Hierro,Raffaella Giacchino,Cristiana Barbera,Lucia Zancan,Carlo Crivellaro,Etienne Sokal,Chiara Azzari,Maria Guido,Flavia Bortolotti +10 more
TL;DR: Pediatric HCV infection is usually mild, but few patients, especially those who are perinatally infected, clear viremia in the medium-term follow-up, and the higher rates of fibrosis observed in older patients suggest the possibility of an insidious progression of HCV-associated liver disease.
Journal ArticleDOI
Clinical features and progression of perinatally acquired hepatitis C virus infection.
Massimo Resti,Paloma Jara,Loreto Hierro,Chiara Azzari,Raffaella Giacchino,Giovanna Zuin,Lucia Zancan,Sabrina Pedditzi,Flavia Bortolotti +8 more
TL;DR: The early stage of acquired perinatally HCV infection is characterized by a wide range of ALT abnormalities, suggesting the interaction of multiple host and virus factors, and high ALT levels at onset seem to offer greater opportunity of biochemical remission and loss of viremia during follow‐up.
Journal ArticleDOI
Chronic Hepatitis C in Children: The Pathological and Clinical Spectrum
Maria Guido,Massimo Rugge,Paloma Jara,Loreto Hierro,Raffaella Giacchino,J. Larrauri,Lucia Zancan,Gioacchino Leandro,Carla E. Marino,Fiorella Balli,A. Bagni,A. Timitilli,Flavia Bortolotti +12 more
TL;DR: In otherwise healthy children, chronic hepatitis C is a morphologically mild disease in most cases and fibrosis increases with the duration of disease, suggesting that end-stage disease may develop in young adulthood.
Journal ArticleDOI
High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin.
Stefan Wirth,Carmen Ribes-Koninckx,Maria Angeles Calzado,Flavia Bortolotti,Lucia Zancan,Paloma Jara,M Shelton,Nanda Kerkar,Marcela Galoppo,Alejandra Pedreira,Norberto Rodriguez-Baez,Mirta Ciocca,Alain Lachaux,F. Lacaille,Thomas Lang,Ulrike Kullmer,Wolf Deitrich Huber,Teresita Gonzalez,Henry Pollack,Estella M. Alonso,Pierre Broué,Jyoti Ramakrishna,Deborah A. Neigut,Antonio Del Valle-Segarra,Bessie Hunter,Zachery Goodman,Christine Xu,Hanzhe Zheng,Stephanie Noviello,Vilma Sniukiene,Clifford A. Brass,Janice K. Albrecht +31 more
TL;DR: Therapy with PEG-IFN alfa-2b plus RBV in children and adolescents with chronic hepatitis C offers favorable efficacy, reduced injection frequency, and an acceptable safety profile.